Inside Bioxyne: The ASX’s Profitable Play on Medicinal Cannabis, MDMA & Psilocybin

In this episode, we sit down with Sam Watson, managing director of Bioxyne (BXN:ASX), to unpack how the company is positioning itself at the intersection of medicinal cannabis, psychedelics, and precision medicine. We dive into the regulatory landscape across the UK and Australia, breaking down how prescribing works and why navigating compliance is critical to success. A key focus is GMP certification, and how maintaining pharmaceutical-grade standards builds trust and creates a competitive edge. We also explore Bioxyne’s strategy of manufacturing finished products, from inhalable flower to fast-growing formats like pastilles, and how they’ve carved out a strong position in the Australian market. Beyond cannabis, the conversation touches on emerging therapies like psilocybin and MDMA, and the growing opportunity to treat conditions like depression and PTSD. Finally, Sam shares Bioxyne’s unique approach to commercialising investigational medicines earlier to accelerate growth while managing risk. This is one of the fastest-growing sectors in healthcare — and Bioxyne is one of the few ASX-listed names that’s doing it profitably.